Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma

BackgroundChildren with craniopharyngiomas (CPs) typically suffer from a life-long chronic disease. The younger the child, the more vulnerable the maturing brain is to invasive therapies such as surgery or radiotherapy. Therefore, treatment modalities facilitating avoidance or delay of invasive ther...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Cora Hedrich, Priya Patel, Lukas Haider, Tracey Taylor, Elaine Lau, Roxanne Hook, Christian Dorfer, Karl Roessler, Natalia Stepien, Maria Aliotti Lippolis, Hannah Schned, Clara Koeller, Lisa Mayr, Amedeo A. Azizi, Andreas Peyrl, Bienvenido Ros Lopez, Alvaro Lassaletta, Julie Bennett, Johannes Gojo, Ute Bartels
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2024-07-01
Rangatū:	Frontiers in Oncology
Ngā marau:	craniopharyngioma intracystic treatment peginterferon alfa-2a pediatric neurooncology pediatric neurosurgery
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1401761/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!